WO2005039550A2 - Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds - Google Patents
Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds Download PDFInfo
- Publication number
- WO2005039550A2 WO2005039550A2 PCT/EP2004/052639 EP2004052639W WO2005039550A2 WO 2005039550 A2 WO2005039550 A2 WO 2005039550A2 EP 2004052639 W EP2004052639 W EP 2004052639W WO 2005039550 A2 WO2005039550 A2 WO 2005039550A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- substituted
- compound
- cbi
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 256
- 230000000694 effects Effects 0.000 title claims abstract description 52
- 238000011284 combination treatment Methods 0.000 title description 5
- 208000008589 Obesity Diseases 0.000 claims abstract description 160
- 235000020824 obesity Nutrition 0.000 claims abstract description 160
- 238000011282 treatment Methods 0.000 claims abstract description 131
- -1 panclicins Chemical compound 0.000 claims abstract description 105
- 239000003814 drug Substances 0.000 claims abstract description 88
- 238000011321 prophylaxis Methods 0.000 claims abstract description 81
- 230000000366 juvenile effect Effects 0.000 claims abstract description 78
- 150000003839 salts Chemical class 0.000 claims abstract description 67
- 229940079593 drug Drugs 0.000 claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 50
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical class C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 claims abstract description 46
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229950002397 cetilistat Drugs 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 23
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 claims abstract description 16
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 150000007979 thiazole derivatives Chemical class 0.000 claims abstract description 6
- ZEWJFUNFEABPGL-UHFFFAOYSA-N 1,2,4-triazole-3-carboxamide Chemical class NC(=O)C=1N=CNN=1 ZEWJFUNFEABPGL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 131
- 239000003557 cannabinoid Substances 0.000 claims description 108
- 229930003827 cannabinoid Natural products 0.000 claims description 107
- 108090001060 Lipase Proteins 0.000 claims description 98
- 239000004367 Lipase Substances 0.000 claims description 98
- 102000004882 Lipase Human genes 0.000 claims description 98
- 235000019421 lipase Nutrition 0.000 claims description 98
- 230000002401 inhibitory effect Effects 0.000 claims description 86
- 230000003042 antagnostic effect Effects 0.000 claims description 63
- 239000000651 prodrug Substances 0.000 claims description 61
- 229940002612 prodrug Drugs 0.000 claims description 61
- 229910052757 nitrogen Inorganic materials 0.000 claims description 58
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 56
- 125000000623 heterocyclic group Chemical group 0.000 claims description 51
- 125000005842 heteroatom Chemical group 0.000 claims description 49
- 125000001424 substituent group Chemical group 0.000 claims description 48
- 102000005962 receptors Human genes 0.000 claims description 47
- 108020003175 receptors Proteins 0.000 claims description 47
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 43
- 125000003545 alkoxy group Chemical group 0.000 claims description 42
- 229910052760 oxygen Inorganic materials 0.000 claims description 42
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 42
- 229910052717 sulfur Inorganic materials 0.000 claims description 38
- 125000004076 pyridyl group Chemical group 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 32
- 125000003342 alkenyl group Chemical group 0.000 claims description 31
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 31
- 125000001153 fluoro group Chemical group F* 0.000 claims description 30
- 125000001544 thienyl group Chemical group 0.000 claims description 30
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000000468 ketone group Chemical group 0.000 claims description 26
- 229920006395 saturated elastomer Polymers 0.000 claims description 26
- 229920000642 polymer Polymers 0.000 claims description 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
- 125000002950 monocyclic group Chemical group 0.000 claims description 23
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 22
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 21
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000006413 ring segment Chemical group 0.000 claims description 20
- 208000006011 Stroke Diseases 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 17
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 16
- 125000002619 bicyclic group Chemical group 0.000 claims description 16
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 16
- 125000001624 naphthyl group Chemical group 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 206010015037 epilepsy Diseases 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 208000020016 psychiatric disease Diseases 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 208000012902 Nervous system disease Diseases 0.000 claims description 9
- 208000025966 Neurological disease Diseases 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 8
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 8
- 230000005062 synaptic transmission Effects 0.000 claims description 8
- 125000004306 triazinyl group Chemical group 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 201000006474 Brain Ischemia Diseases 0.000 claims description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 6
- 206010012335 Dependence Diseases 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 6
- 208000014094 Dystonic disease Diseases 0.000 claims description 6
- 206010014612 Encephalitis viral Diseases 0.000 claims description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 206010019196 Head injury Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000026139 Memory disease Diseases 0.000 claims description 6
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 6
- 206010028813 Nausea Diseases 0.000 claims description 6
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 208000034189 Sclerosis Diseases 0.000 claims description 6
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 208000027520 Somatoform disease Diseases 0.000 claims description 6
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 6
- 208000016620 Tourette disease Diseases 0.000 claims description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
- 206010044565 Tremor Diseases 0.000 claims description 6
- 206010047700 Vomiting Diseases 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000002490 cerebral effect Effects 0.000 claims description 6
- 206010008118 cerebral infarction Diseases 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 230000006735 deficit Effects 0.000 claims description 6
- 206010013663 drug dependence Diseases 0.000 claims description 6
- 208000010118 dystonia Diseases 0.000 claims description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 6
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 230000008693 nausea Effects 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 208000021722 neuropathic pain Diseases 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 208000027753 pain disease Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 208000023504 respiratory system disease Diseases 0.000 claims description 6
- 230000036303 septic shock Effects 0.000 claims description 6
- 208000020431 spinal cord injury Diseases 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 230000009529 traumatic brain injury Effects 0.000 claims description 6
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 6
- 201000002498 viral encephalitis Diseases 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
- 208000027559 Appetite disease Diseases 0.000 claims description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 229930194542 Keto Natural products 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 2
- 229940127470 Lipase Inhibitors Drugs 0.000 abstract description 20
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 abstract description 14
- 229960001243 orlistat Drugs 0.000 abstract description 14
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract description 4
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 3
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 3
- 229940040461 lipase Drugs 0.000 description 73
- 239000005557 antagonist Substances 0.000 description 30
- 238000002844 melting Methods 0.000 description 17
- 230000008018 melting Effects 0.000 description 17
- 229940086609 Lipase inhibitor Drugs 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 230000000144 pharmacologic effect Effects 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 208000021017 Weight Gain Diseases 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 235000019786 weight gain Nutrition 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 12
- 108050006759 Pancreatic lipases Proteins 0.000 description 12
- 230000003389 potentiating effect Effects 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000218236 Cannabis Species 0.000 description 11
- 102000019280 Pancreatic lipases Human genes 0.000 description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 11
- 229940116369 pancreatic lipase Drugs 0.000 description 10
- 230000004584 weight gain Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 208000007683 Pediatric Obesity Diseases 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 239000003693 atypical antipsychotic agent Substances 0.000 description 6
- 229940127236 atypical antipsychotics Drugs 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- UNBMQQNYLCPCHS-UHFFFAOYSA-N Ebelactone B Natural products CCC(C)C(O)C(C)C(=O)C(C)C=C(C)CC(C)C1OC(=O)C1CC UNBMQQNYLCPCHS-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- UNBMQQNYLCPCHS-VYNDPHDASA-N ebelactone b Chemical compound CC[C@@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)\C=C(/C)C[C@H](C)[C@@H]1OC(=O)[C@H]1CC UNBMQQNYLCPCHS-VYNDPHDASA-N 0.000 description 5
- 239000004031 partial agonist Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000011866 long-term treatment Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 3
- 0 *c1nc(C(O*)=O)n[n]1* Chemical compound *c1nc(C(O*)=O)n[n]1* 0.000 description 3
- NSPMIYGKQJPBQR-CVMUNTFWSA-N 1h-1,2,4-triazole Chemical class [13CH]=1[15N]=[13CH][15NH][15N]=1 NSPMIYGKQJPBQR-CVMUNTFWSA-N 0.000 description 3
- YYPXNAAEYOJYES-UHFFFAOYSA-N 2-amino-3,1-benzoxazin-4-one Chemical class C1=CC=C2C(=O)OC(N)=NC2=C1 YYPXNAAEYOJYES-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 3
- 108050007331 Cannabinoid receptor Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- MHDFJESNGMDHQD-UHFFFAOYSA-N dimethyl 2-aminopropanedioate Chemical compound COC(=O)C(N)C(=O)OC MHDFJESNGMDHQD-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- YZXBAPSDXZZRGB-UHFFFAOYSA-N icosa-5,8,11,14-tetraenoic acid Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(O)=O YZXBAPSDXZZRGB-UHFFFAOYSA-N 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- ZEZPYKWZOOJYIZ-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-(2,4-dichlorophenyl)-1,2,4-triazole-3-carbonyl chloride Chemical compound C=1C=CC=C(Cl)C=1N1N=C(C(=O)Cl)N=C1C1=CC=C(Cl)C=C1Cl ZEZPYKWZOOJYIZ-UHFFFAOYSA-N 0.000 description 2
- HCNMVIBIGGUPKA-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1N1N=C(C(=O)O)N=C1C1=CC=C(Cl)C=C1Cl HCNMVIBIGGUPKA-UHFFFAOYSA-N 0.000 description 2
- HXISEKWXKPQBLA-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-pentyl-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1N=C(C(=O)NCCCCC)N=C1C1=CC=C(Cl)C=C1Cl HXISEKWXKPQBLA-UHFFFAOYSA-N 0.000 description 2
- HGRBNXUCZUTDDA-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxylic acid Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1N=C(C(=O)O)N=C1C1=CC=C(Cl)C=C1 HGRBNXUCZUTDDA-UHFFFAOYSA-N 0.000 description 2
- 244000141218 Alpinia officinarum Species 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- GPDYXZCYXCZIDY-UHFFFAOYSA-N dimethyl 2-[(4-chlorobenzoyl)amino]propanedioate Chemical compound COC(=O)C(C(=O)OC)NC(=O)C1=CC=C(Cl)C=C1 GPDYXZCYXCZIDY-UHFFFAOYSA-N 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- KDMWGAKWRNCERZ-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1N=C(C(=O)OC)N=C1C1=CC=C(Cl)C=C1 KDMWGAKWRNCERZ-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical class O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- 229940117972 triolein Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 description 1
- 150000000178 1,2,4-triazoles Chemical class 0.000 description 1
- WMNUOPCDFASANM-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-n-piperidin-1-yl-5-pyridin-2-yl-1,2,4-triazole-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1N1C(C=2N=CC=CC=2)=NC(C(=O)NN2CCCCC2)=N1 WMNUOPCDFASANM-UHFFFAOYSA-N 0.000 description 1
- WWJAEAWIYPROKM-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-n-piperidin-1-yl-5-pyridin-3-yl-1,2,4-triazole-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1N1C(C=2C=NC=CC=2)=NC(C(=O)NN2CCCCC2)=N1 WWJAEAWIYPROKM-UHFFFAOYSA-N 0.000 description 1
- OSPQSSUSIPAYEC-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-(2,5-dichlorophenyl)-1,2,4-triazole-3-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1N1N=C(C(=O)O)N=C1C1=CC(Cl)=CC=C1Cl OSPQSSUSIPAYEC-UHFFFAOYSA-N 0.000 description 1
- UVXRJFZHLIVKJH-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-(1-ethynylcyclohexyl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2(CCCCC2)C#C)=N1 UVXRJFZHLIVKJH-UHFFFAOYSA-N 0.000 description 1
- QUVINPQBZYNQTA-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-(2,2,2-trifluoroethyl)-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1N=C(C(=O)NCC(F)(F)F)N=C1C1=CC=C(Cl)C=C1Cl QUVINPQBZYNQTA-UHFFFAOYSA-N 0.000 description 1
- GVGJQGDMVLZDLD-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-(2,2-dimethylpropyl)-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1N=C(C(=O)NCC(C)(C)C)N=C1C1=CC=C(Cl)C=C1Cl GVGJQGDMVLZDLD-UHFFFAOYSA-N 0.000 description 1
- YINXKWBWQOKQHY-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-(2,3-dihydro-1h-inden-2-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2CC3=CC=CC=C3C2)=N1 YINXKWBWQOKQHY-UHFFFAOYSA-N 0.000 description 1
- SFHSROKBKXNVAQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-(2-methylcyclohexyl)-1,2,4-triazole-3-carboxamide Chemical compound CC1CCCCC1NC(=O)C1=NN(C=2C=CC(Cl)=CC=2)C(C=2C(=CC(Cl)=CC=2)Cl)=N1 SFHSROKBKXNVAQ-UHFFFAOYSA-N 0.000 description 1
- HYVXEZOGBAKXJT-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-(3-ethylpent-1-yn-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1N=C(C(=O)NC(CC)(CC)C#C)N=C1C1=CC=C(Cl)C=C1Cl HYVXEZOGBAKXJT-UHFFFAOYSA-N 0.000 description 1
- MUUVZOGHNGKBJU-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-(4-methylcyclohexyl)-1,2,4-triazole-3-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=NN(C=2C=CC(Cl)=CC=2)C(C=2C(=CC(Cl)=CC=2)Cl)=N1 MUUVZOGHNGKBJU-UHFFFAOYSA-N 0.000 description 1
- RNKGISKNEJHUHZ-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-(4-propan-2-ylpiperazin-1-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1CN(C(C)C)CCN1NC(=O)C1=NN(C=2C=CC(Cl)=CC=2)C(C=2C(=CC(Cl)=CC=2)Cl)=N1 RNKGISKNEJHUHZ-UHFFFAOYSA-N 0.000 description 1
- DEAMOJANEKHTTR-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-(5,5,5-trifluoropentyl)-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1N=C(C(=O)NCCCCC(F)(F)F)N=C1C1=CC=C(Cl)C=C1Cl DEAMOJANEKHTTR-UHFFFAOYSA-N 0.000 description 1
- BREDOQJGQOTWAC-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-(5-fluoropentyl)-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1N=C(C(=O)NCCCCCF)N=C1C1=CC=C(Cl)C=C1Cl BREDOQJGQOTWAC-UHFFFAOYSA-N 0.000 description 1
- ZXUOZGOVQUECFE-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-[(2-methylpropan-2-yl)oxy]-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1N=C(C(=O)NOC(C)(C)C)N=C1C1=CC=C(Cl)C=C1Cl ZXUOZGOVQUECFE-UHFFFAOYSA-N 0.000 description 1
- XBCRJKWIDKPEDB-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-[3-(trifluoromethyl)phenyl]-1,2,4-triazole-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C2=NN(C(C=3C(=CC(Cl)=CC=3)Cl)=N2)C=2C=CC(Cl)=CC=2)=C1 XBCRJKWIDKPEDB-UHFFFAOYSA-N 0.000 description 1
- ACAJGPWTGOEXCV-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-morpholin-4-yl-1,2,4-triazole-3-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCOCC2)=N1 ACAJGPWTGOEXCV-UHFFFAOYSA-N 0.000 description 1
- CZKQLFXVEIWINO-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-piperidin-1-yl-1,2,4-triazole-3-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCCCC2)=N1 CZKQLFXVEIWINO-UHFFFAOYSA-N 0.000 description 1
- KULSZGLTHXEXJZ-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-pyrrolidin-1-yl-1,2,4-triazole-3-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCCC2)=N1 KULSZGLTHXEXJZ-UHFFFAOYSA-N 0.000 description 1
- NICQDKFLDCJRFY-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,5-dichlorophenyl)-n-(1-ethynylcyclohexyl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC=C(Cl)C=2)Cl)=NC(C(=O)NC2(CCCCC2)C#C)=N1 NICQDKFLDCJRFY-UHFFFAOYSA-N 0.000 description 1
- ITSKOOCCGQNZHE-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,5-dichlorophenyl)-n-(2,2-dimethylpropyl)-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1N=C(C(=O)NCC(C)(C)C)N=C1C1=CC(Cl)=CC=C1Cl ITSKOOCCGQNZHE-UHFFFAOYSA-N 0.000 description 1
- GJXXNXKGMLJWLM-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,5-dichlorophenyl)-n-(2-methylcyclohexyl)-1,2,4-triazole-3-carboxamide Chemical compound CC1CCCCC1NC(=O)C1=NN(C=2C=CC(Cl)=CC=2)C(C=2C(=CC=C(Cl)C=2)Cl)=N1 GJXXNXKGMLJWLM-UHFFFAOYSA-N 0.000 description 1
- WULBCTHLZAHOTN-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,5-dichlorophenyl)-n-(4-methylcyclohexyl)-1,2,4-triazole-3-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=NN(C=2C=CC(Cl)=CC=2)C(C=2C(=CC=C(Cl)C=2)Cl)=N1 WULBCTHLZAHOTN-UHFFFAOYSA-N 0.000 description 1
- RDRKMKIBLPEGRU-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-cycloheptyl-5-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2CCCCCC2)=N1 RDRKMKIBLPEGRU-UHFFFAOYSA-N 0.000 description 1
- YGFHFZASBCCUMF-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-cycloheptyl-5-(2,5-dichlorophenyl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC=C(Cl)C=2)Cl)=NC(C(=O)NC2CCCCCC2)=N1 YGFHFZASBCCUMF-UHFFFAOYSA-N 0.000 description 1
- GZMKHEUDMGOEHV-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-cyclohexyl-5-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2CCCCC2)=N1 GZMKHEUDMGOEHV-UHFFFAOYSA-N 0.000 description 1
- LWLHZWQCHMKPNO-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-cyclooctyl-5-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2CCCCCCC2)=N1 LWLHZWQCHMKPNO-UHFFFAOYSA-N 0.000 description 1
- XUJDPKTVIBSWIX-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-cyclooctyl-5-(2,5-dichlorophenyl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC=C(Cl)C=2)Cl)=NC(C(=O)NC2CCCCCCC2)=N1 XUJDPKTVIBSWIX-UHFFFAOYSA-N 0.000 description 1
- XQBHAZDVLGNSOJ-UHFFFAOYSA-N 1-(4-ethenylphenyl)-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC=C(C=C)C=C1 XQBHAZDVLGNSOJ-UHFFFAOYSA-N 0.000 description 1
- WEHCTVZAWORDST-UHFFFAOYSA-N 1-(4-methylphenyl)-5-phenyl-n-pyridin-2-yl-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(C)=CC=C1N1C(C=2C=CC=CC=2)=NC(C(=O)NC=2N=CC=CC=2)=N1 WEHCTVZAWORDST-UHFFFAOYSA-N 0.000 description 1
- XIRPMPKSZHNMST-UHFFFAOYSA-N 1-ethenyl-2-phenylbenzene Chemical group C=CC1=CC=CC=C1C1=CC=CC=C1 XIRPMPKSZHNMST-UHFFFAOYSA-N 0.000 description 1
- IGGDKDTUCAWDAN-UHFFFAOYSA-N 1-vinylnaphthalene Chemical compound C1=CC=C2C(C=C)=CC=CC2=C1 IGGDKDTUCAWDAN-UHFFFAOYSA-N 0.000 description 1
- KQCMTOWTPBNWDB-UHFFFAOYSA-N 2,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C=C1Cl KQCMTOWTPBNWDB-UHFFFAOYSA-N 0.000 description 1
- CEOCVKWBUWKBKA-UHFFFAOYSA-N 2,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1Cl CEOCVKWBUWKBKA-UHFFFAOYSA-N 0.000 description 1
- RSINFFVFOTUDEC-UHFFFAOYSA-N 2,5-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC(Cl)=CC=C1Cl RSINFFVFOTUDEC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- LMHHFZAXSANGGM-UHFFFAOYSA-N 2-aminoindane Chemical compound C1=CC=C2CC(N)CC2=C1 LMHHFZAXSANGGM-UHFFFAOYSA-N 0.000 description 1
- UABZBFJRDPRXJR-UHFFFAOYSA-N 2-methylidenebutanoate;trimethylazanium Chemical compound C[NH+](C)C.CCC(=C)C([O-])=O UABZBFJRDPRXJR-UHFFFAOYSA-N 0.000 description 1
- UWRZIZXBOLBCON-UHFFFAOYSA-N 2-phenylethenamine Chemical compound NC=CC1=CC=CC=C1 UWRZIZXBOLBCON-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- MZSRNWVKWGEZPH-UHFFFAOYSA-N 5-(2,4-dichlorophenyl)-n-piperidin-1-yl-1-[4-(trifluoromethyl)phenyl]-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCCCC2)=N1 MZSRNWVKWGEZPH-UHFFFAOYSA-N 0.000 description 1
- CYAYCOCJAVHQSD-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid Chemical compound CC=1C(C(O)=O)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 CYAYCOCJAVHQSD-UHFFFAOYSA-N 0.000 description 1
- JSLMARBSBFEJNP-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-n-[(2-methylpropan-2-yl)oxy]-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1N=C(C(=O)NOC(C)(C)C)N=C1C1=CC=C(Cl)C=C1 JSLMARBSBFEJNP-UHFFFAOYSA-N 0.000 description 1
- SXVJCJPSMGURII-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-n-pentyl-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1N=C(C(=O)NCCCCC)N=C1C1=CC=C(Cl)C=C1 SXVJCJPSMGURII-UHFFFAOYSA-N 0.000 description 1
- HIIGMMBWIODVIJ-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-n-piperidin-1-yl-1,2,4-triazole-3-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C1=NC(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl HIIGMMBWIODVIJ-UHFFFAOYSA-N 0.000 description 1
- OWSCURRUEHCKFI-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-n-pyrrolidin-1-yl-1,2,4-triazole-3-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C1=NC(C(=O)NN2CCCC2)=NN1C1=CC=C(Cl)C=C1Cl OWSCURRUEHCKFI-UHFFFAOYSA-N 0.000 description 1
- FJLQKGWCOSPWBK-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-cyclohexyl-1-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=NC(C(=O)NC2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl FJLQKGWCOSPWBK-UHFFFAOYSA-N 0.000 description 1
- DAQCUXYFZBBWOG-UHFFFAOYSA-N 5-dodecoxy-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OCCCCCCCCCCCC)=NN1C1=CC=C(OC(F)(F)F)C=C1 DAQCUXYFZBBWOG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 241000722948 Apocynum cannabinum Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- WOISDAHQBUYEAF-UHFFFAOYSA-N Ebelactone A Natural products CCC(C)C(O)C(C)C(=O)C(C)C=C(C)CC(C)C1OC(=O)C1C WOISDAHQBUYEAF-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 206010056465 Food craving Diseases 0.000 description 1
- LYISDADPVOHJBJ-UHFFFAOYSA-N Galangin 3-methyl ether Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(OC)=C1C1=CC=CC=C1 LYISDADPVOHJBJ-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 235000015928 Hibiscus cannabinus Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 241000958270 Kitasatospora aburaviensis Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101001064310 Rattus norvegicus Gastric triacylglycerol lipase Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000946767 Streptomyces toxytricini Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- KCNKJCHARANTIP-SNAWJCMRSA-N allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine Chemical compound C=1OC2=CC(OC/C=C/CN(CC=C)C)=CC=C2C=1C1=CC=C(Br)C=C1 KCNKJCHARANTIP-SNAWJCMRSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- MPMBRWOOISTHJV-UHFFFAOYSA-N but-1-enylbenzene Chemical compound CCC=CC1=CC=CC=C1 MPMBRWOOISTHJV-UHFFFAOYSA-N 0.000 description 1
- 230000003375 cannabimimetic effect Effects 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 235000019620 fat digestibility Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- ZIJIXDGGPCSBSI-UHFFFAOYSA-N n,1-bis(4-chlorophenyl)-5-(2,5-dichlorophenyl)-n-methyl-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C(=NN1C=2C=CC(Cl)=CC=2)N=C1C1=CC(Cl)=CC=C1Cl ZIJIXDGGPCSBSI-UHFFFAOYSA-N 0.000 description 1
- IQBDRJGQTWPMPY-UHFFFAOYSA-N n-(3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl)-1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CC3CCCC3C2)=N1 IQBDRJGQTWPMPY-UHFFFAOYSA-N 0.000 description 1
- ZRMUTFIKQCOTTN-UHFFFAOYSA-N n-(azepan-1-yl)-1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCCCCC2)=N1 ZRMUTFIKQCOTTN-UHFFFAOYSA-N 0.000 description 1
- BOCHGCYRQIIEMK-UHFFFAOYSA-N n-tert-butyl-1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1N=C(C(=O)NC(C)(C)C)N=C1C1=CC=C(Cl)C=C1Cl BOCHGCYRQIIEMK-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- SFBTTWXNCQVIEC-UHFFFAOYSA-N o-Vinylanisole Chemical compound COC1=CC=CC=C1C=C SFBTTWXNCQVIEC-UHFFFAOYSA-N 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 208000006155 precocious puberty Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to novel therapeutic and/or prophylactic uses of compounds showing CB antagonistic activity and to pharmaceutical compositions containing one or more of these compounds as an active component for the novel uses.
- the compounds addressed in this invention show Cannabis-1 (CBi) receptor antagonistic activity and may provide outstanding utility for the novel medical uses provided by the present invention.
- said compounds with CBi- antagonistic activity may be used in combination with a further active principle, and to pharmaceutical compositions containing at least one of these CB ⁇ antagonistic compounds in combination with said further active principle for the treatment and/or prophylaxis of obesity.
- the combination provided by the present invention of said compounds having Cannabis-1 (CBi) receptor antagonistic activity with said further active principle are of particular utility for treating of obesity.
- Cannabinoids are present in the Indian hemp Cannabis Sativa L. and have been used as medicinal agents for centuries (Mechoulam, R.; Feigenbaum, J.J. Prog. Med. Chem. 1987, 24, 159). However, only within the past ten years the research in the cannabinoid area has revealed pivotal information on cannabinoid receptors and their (endogenous) agonists and antagonists. The discovery and the subsequent cloning of two different subtypes of Cannabinoid receptors (CBi and CB 2 ) stimulated the search for novel cannabinoid receptor antagonists (Munro, S.; Thomas, K.L.; Abu-Shaar, M. Nature 1993, 365, 61.
- Inparticular said compounds with cannabis CBi-receptor activity have been suggested for use in the treatment of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addiction, appetence, drug dependence and neurological disorders such as neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischemia, cerebral apoplexy, craniocerebral trauma, stroke, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelinisation related disorders, as well as for the treatment of pain disorders, including neuropathic pain disorders, and other diseases involving cannabinoid neurotransmission, including the treatment of septic shock, glaucoma, cancer, diabetes, emesis, nausea, asthma, respiratory diseases, gastrointestinal disorders, gastric ulcers,
- the international patent application WO 03/026647 describes a group of novel compounds which are 4,5-dihydro-lH-pyrazole derivatives and have the formula (I) defined below.
- These 4,5-dihydro-lH-pyrazole derivatives are potent cannabinoid (CBi) receptor antagonists with utility for the treatment of diseases connected with disorders of the cannabinoid system.
- the compounds have the general formula (I) wherein the symbols have the meanings given below in the specification, and show in particular potent CBi antagonistic activity.
- the international patent application WO 03/027076 describes a group of novel compounds which are 1H-imidazole derivatives and have the formula (II) defined below.
- These 1H-imidazole derivatives are potent cannabinoid ( CB f ) receptor agonists, partial agonists or antagonists, useful for the treatment of psychiatric and neurological disorders, as well as and other diseases involving cannabinoid neurotransmission.
- CB f cannabinoid receptor agonists
- partial agonists or antagonists useful for the treatment of psychiatric and neurological disorders, as well as and other diseases involving cannabinoid neurotransmission.
- the compounds have the general formula (II) wherein the symbols have the meanings given below in the specification.
- the international patent application WO 03/026648 describes a group of novel compounds which are also 4,5-dihydro-lH-pyrazole derivatives and have one of the formulas (III) defined below.
- These 4,5-dihydro-lH-pyrazole derivatives again are potent cannabinoid (CB1) receptor antagonists with utility for the treatment of diseases connected with disorders of the cannabinoid system.
- CB1 cannabinoid
- the compounds have the general formula (Ilia) or (1Mb) wherein the symbols have the meanings given in the specification below.
- the international patent application WO 03/078413 describes a group of novel compounds which are thiazole derivatives and have of the formula (IV) defined below. These thiazole derivatives are potent antagonists, agonists or partial agonists of the cannabinoid CBi-receptor, with utility for the treatment of diseases connected with disorders of the cannabinoid system.
- the compounds have the general formula (IV) wherein the symbols have the meanings given in the specification below.
- a further objective is to provide particular beneficial combination treatments and medicaments therefore for the treatment and/or prophylaxis of obesity in patients of any age, e.g. in adolescent as well as in juvenile patients, wherein the compounds with CBi antagonistic activity used according to the present invention are combined with a further active principle for the treatment of obesity.
- the invention pertains to a combination of a compound with CBi- receptor activity having one of the formulas (I), (II), (III), (IV) or (V) as subsequently defined, or a prodrug, tautomer or salt thereof, preferably of a CBi receptor antagonistic compound or a prodrug, tautomer or salt thereof, with at least one lipase inhibiting compound.
- the compound with CBi-receptor activity having one of the formulas (I), (II), (III), (IV) or (V) as subsequenzly defined, or a prodrug, tautomer or salt thereof, preferably the CBi receptor antagonistic compound or a prodrug, tautomer or salt thereof, is in combination with at least one lipase inhibiting compound selected from the group of lipase inhibiting polymers, orlistat, panclicins, ATL-962 and lipstatin.
- the CB antagonists of formulas (I), (II), (III), (IV) and/or (V), prodrugs thereof, tautomers thereof and salts thereof show a unique pharmacological profile and therefore are particularly suited for the use in the manufacture of a medicaments for the treatment and/or prophylaxis of obesity patients, in particular of obesity in juvenile patients and/or drug induced obesity in juvenile, as well as adolescent, patients.
- CBi-antagonistic compounds of formulas (I), (II), (III), (IV) and/or (V), prodrugs thereof, tautomers thereof and salts thereof are highly valuable in providing medicaments for pediatric use on the one hand, and for the general use in drug induced obesity.
- the compounds used according to the invention are suitable also for use in pediatric treatment and/or prophylaxis of other disorders than juvenile obesity and drug induced obesity in juvenile patients.
- the other disorders include those known from the literature for the concerned compounds with activity on the cannabis CBi-receptor, and e.g.
- the pediatric treatment and/or prophylaxis may also pertain to psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, obesity, dis orders, addiction, appetence, drug dependence and neurological disorders such as neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischemia, cerebral apoplexy, craniocerebral trauma, stroke, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelinisation related disorders, as well as for the pediatric treatment of pain disorders, including neuropathic pain disorders, and other diseases involving cannabinoid neurotransmission, including the pediatric treatment of septic shock, glaucoma, cancer, diabetes, emesis, nausea, asthma, respiratory diseases, gastrointestinal disorders, gastric ulcers, diarrhoea and
- the CBi antagonistic compounds used in the present the invention can be obtained according to known methods. Suitable ways of synthesis for the compounds used according to the present invention are described in the state of the art, e.g. in the documents cited in the present application and incorporated by reference.
- CBi antagonistic compounds of the formulas (I), (II), (III), (IV) and/or (V), as well as prodrugs, tautomers and salts thereof, due to their unique pharmacological profile are particularly suited in combination with at least one lipase inhibiting compound
- lipase inhibitor for the use in the manufacture of a medicaments for the treatment and/or prophylaxis of obesity, including in particular the treatment and/or prophylaxis of obesity in juvenile patients and/or drug induced obesity in juvenile as well as adolescent patients.
- CB antagonistic compound as defined herein with at least one lipase inhibiting compound are highly valuable in providing medicaments for the treatment and/or prophylaxis of obesity in general, e.g. in adolescent patients of any age, and particularly also in pediatric or juvenile obesity, and also in drug induced obesity in adolescent and juvenile patients.
- the present invention is based on the surprising finding that the CBi antagonistic compounds of the formulas (I) being 4,5-dihydro-lH-pyrazole derivatives, (II) being 1H-lmidazole derivatives , (III) being also 4,5-dihydro-lH- pyrazole derivatives, (IV) being thiazole derivatives or (V) being 1 H-1 ,2,4-triazole- 3-carboxamide derivatives, which are antagonists of the cannabis CBi-receptor, prodrugs thereof, tautomers thereof and salts thereof, due to their unique pharmacological profile are particularly suited in combination with at least one lipase inhibiting compound for the use in the manufacture of a medicament for the treatment and/or prophylaxis of obesity in general, e.g.
- each of the compounds with the formulas (I), (II), III), IV or (V), together with lipase inhibiting compounds are highly valuable in providing medicaments for the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also in pediatric or juvenile obesity, and in drug induced obesity.
- the compounds of the formulas (I), (II), III), (IV) or (V) used in the present the invention can be obtained according to known methods.
- a suitable synthesis for the compounds of the formulas (I), (II), III), (IV) used according to the present invention is described in the international patent applications WO 03/026647, WO 03/027076, WO 03/078413 or WO 03/078413, which are incorporated by reference into this specification.
- Compounds of formula (V) can be prepared according to a recently filed international patent application, which is going to be published in March/April 2004 and is based on the European priority application EP 02078966.5 with priority date 19.09.2002, which is also incorporated by reference into the present specification . Preparation of compounds of formula (V) is also described at the end of this specification.
- the present invention is based on the surprising finding that the 4,5-dihydro-l H-pyrazole derivatives of the formula (I) which are potent and selective antagonists of the cannabis CBi-receptor, prodrugs thereof, tautomers thereof and salts thereof:
- R and Ri independently represent phenyl, thienyl or pyridyl which groups may be substituted with 1, 2, 3 or 4 substituents Y, which can be the same or different, from the group d -3 -alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C ⁇ -2 )-amino, mono- or dialkyl (C ⁇ -2 )-amido, (C ⁇ -3 )-alkyl sulfonyl, dimethylsulfamido, C 1-3 -alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, or R and/or Ri represent naphtyl,
- R 2 represents hydrogen, hydroxy, C ⁇ -3 -alkoxy, acetyloxy or propionyloxy
- R 3 represents a hydrogen atom or a branched or unbranched C ⁇ -8 alkyl group or a C 3 - 7 cycloalkyl group which alkyl group or cycloalkyl group may be substituted with a hydroxy group,
- - t represents a C 2- ⁇ 0 branched or unbranched heteroalkyl group, C ⁇ s non- aromatic heterocycloalkyl group or non -aromatic heterocycloalkyl-alkyl group which groups contain one or more heteroatoms from the group (O, N, S) or a -SO 2 - group, which C 2- ⁇ 0 branched or unbranched heteroalkyl group, C 3 - 8 non-aromatic heterocycloalkyl group or C4-10 non-aromatic heterocycloalkyl-alkyl group may be substituted with a keto group, trifluoromethyl group, C ⁇ -3 alkyl group, hydroxy, amino, monoalkylamino, or dialkylamino group or a fluoro atom, or R 4 represents an amino, hydroxy, phenoxy or benzyloxy group, or R* represents a C ⁇ -8 alkoxy, C 3 - 8 alkenyl, Cs- ⁇ cycloalkenyl
- R 6 and R 7 are the same or different and represent C 2 ⁇ alkyl , C 2-4 trifluoroalkyl or Re represents a methyl group with the proviso that R represents a C 2 ⁇ alkyl group, or R 6 and R - together with the nitrogen atom to which they are bonded - form a saturated or unsaturated heterocyclic moiety having 4 to 8 ring atoms which heterocyclic moiety may contain an oxygen or sulphur atom or a keto group or -S0 2 - group or an additional nitrogen atom, which saturated or unsaturated heterocyclic moiety may be substituted with a alkyl group, or
- R 3 and R 4 together with the nitrogen atom to which they are bonded form a saturated or unsaturated, monocyclic or bicyclic heterocyclic moiety having 4 to 10 ring atoms, which heterocyclic moiety may contain one or more atoms from the group (O, N, S) or a keto group or -SO 2 - group, which moiety may be substituted with a C 1- alkyl, hydroxyalkyl, phenyl, thienyl, pyridyl, amino, monoalkylaminoalkyl, dialkylaminoalkyl, monoalkylamino, dialkylamino, aminoalkyl, azetidinyl, pyrrolidinyl, piperidinyl or hexahydro-1 H-azepinyl group, - R 5 represents benzyl, phenyl, thienyl or pyridyl which may be substituted with 1 , 2, 3 or 4 substituents Y, wherein
- a lipase inhibiting compound for the use in the manufacture of a medicament for the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also for the treatment and/or prophylaxis of obesity in juvenile patients and/or drug induced obesity in juvenile as well as adolescent patients.
- combinations of the compounds of formula (I) together with lipase inhibiting compounds are highly valuable in providing medicaments for the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also in pediatric or juvenile obesity, and in drug induced obesity.
- At least one centre of chirality is present (at the C position of the 4,5-dihydro-lH- pyrazole moiety) in the compounds of the formula (I).
- the invention relates both to racemates, mixtures of diastereomers and the individual stereoisomers of the compounds having formula (I).
- Particular compounds of interest of formula (I) have the absolute stereoconfiguration at the C 4 position of the 4,5-dihydro-1 H- pyrazole moiety as represented by formula (1 a ).
- the invention also relates both to the E isomer, Z isomer and E/Z mixtures of compounds having formula (I).
- the present invention is based on the surprising finding that the 1H-imidazole derivatives with CBi antagonistic activity of the formula (II), prodrugs thereof and salts thereof, which are potent antagonists on cannabinoid- CBi receptors:
- R represents phenyl, thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl, which groups may be substituted with 1 , 2, 3 or 4 substituents Y, which can be the same or different, from the group C ⁇ -3 - alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C ⁇ -2 )-amino, mono- or dialkyl (C ⁇ -2 )-amido, (C ⁇ -3 )-alkoxycarbonyl, carboxyl, cyano, carbamoyl and acetyl, or R represents naphtyl, with the proviso that when R is 4-pyridinyl, R 4 represents a halogen atom or a
- Ri represents phenyl or pyridinyl, which groups may be substituted with 1 -4 substituents Y, which can be the same or different, wherein Y has the above mentioned meaning, or R represents pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl, which groups may be substituted with 1-2 substituents Y, which can be the same or different or Ri represents a five-membered aromatic heterocyclic ring having one or two heteroatoms from the group (N, O, S), which heteroatoms can be the same or different, which five-membered aromatic heterocyclic ring may be substituted with 1 -2 substituents Y, which can be the same or different or Ri represents naphtyl,
- R 2 represents H, branched or unbranched C ⁇ -8 alkyl, C3-8 cycloalkyl, C3-8 alkenyl, Cs. 8 cycloalkenyl which groups may contain a sulfur, oxygen or nitrogen atom,
- R 3 represents branched or unbranched C 2 - ⁇ alkyl, C ⁇ -8 alkoxy, cycloalkyloxy, cycloalkyl, Cs-in bicycloalkyl, C ⁇ -io tricycloalkyl, C3- 8 alkenyl, Cs- ⁇ cycloalkenyl, which groups may optionally contain one or more heteroatoms from the group (O, N, S) and which groups may be substituted with a hydroxy group or 1-2 C ⁇ -3 alkyl groups or 1-3 fluoro atoms, or R 3 represents a benzyl or phenethyl group which aromatic rings may be substituted with 1-5 substituents Z, which can be the same or different, from the group C ⁇ -3 -alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C ⁇ -2 )- amino, mono- or dialky
- R 5 and R 6 are the same or different and represent branched or unbranched C 1- alkyl, or R 5 and R 6 - together with the nitrogen atom to which they are bonded - form a saturated or unsaturated, monocyclic or bicyclic heterocyclic group having 4 to 10 ring atoms which heterocyclic group contains one or two heteroatoms from the group (N, O, S), which heteroatoms can be the same or different, which heterocyclic group may be substituted with a C ⁇ -3 alkyl group or a hydroxy group, or R 2 and R 3 - together with the nitrogen atom to which they are bonded - form a saturated or unsaturated heterocyclic group having 4 to 10 ring atoms which heterocyclic group contains one or two heteroatoms from the group (N, O, S), which heteroatoms can be the same or different, which heterocyclic group may be substituted with a C ⁇ -3 alkyl group or a hydroxy group, - R 4 represents a hydrogen or halogen atom
- a lipase inhibiting compound for the use in the manufacture of a medicament for the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also for the treatment and/or prophylaxis of obesity in juvenile patients and/or drug induced obesity in juvenile as well as adolescent patients.
- combinations of the compounds of formula (II) together with lipase inhibiting compounds are highly valuable in providing medicaments for the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also in pediatric or juvenile obesity, and in drug induced obesity.
- the present invention is based on the surprising finding that potent and selective antagonism of cannabinoid-CB receptors is present in the 4,5-dihydro-l H-pyrazole derivatives of the formula (Ilia) or (lllb), prodrugs thereof, tautomers thereof and salts thereof: (Ilia) (lllb)
- R and Ri independently represent phenyl, thienyl or pyridyl which groups may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, from the group C ⁇ -3 -alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C ⁇ -2 )-amino, mono- or dialkyl (C ⁇ -2 )-amido, (C ⁇ -3 )-alkyl sulfonyl, dimethylsulfamido, C ⁇ -3 -alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, or R and/or Ri represent naphtyl,
- R 2 represents hydrogen, hydroxy, C 1-3 -alkoxy, acetyloxy or propionyloxy,
- - R 3 represents a hydrogen atom or a branched or unbranched d -8 alkyl group or a C 3 . 7 cycloalkyl group which alkyl group or cycloalkyl group may be substituted with a hydroxy group, - R t represents a hydrogen atom or a branched or unbranched Ci -8 alkyl, C3-8 cycloalkyl, C 2- ⁇ 0 heteroalkyl, C3.
- R 8 alkenyl, Cs- ⁇ cycloalkenyl or C 3 - 9 cycloalkenylalkyl groups may be substituted with a hydroxy group, a trifluoromethyl group, an amino group, a monoalkylamino group or dialkylamino group or a fluoro atom, or R 4 represents a phenyl, benzyl, pyridyl, thienyl, pyridylmethyl or phenethyl group wherein the aromatic rings may be substituted with 1, 2 or 3 of the substituents Y, wherein Y has the meaning as indicated above, or t represents a group NR 6 R 9 with the proviso that R 3 represents a hydrogen atom or a methyl group and wherein R 8 and R 9 are the same or different and represent C ⁇ _ 4 alkyl or C 2-4 trifluoroalkyl or R 8 and R 9 - together with the nitrogen atom to which they are bonded - form a saturated or un
- R 5 represents a naphtyl group or a phenyl group which phenyl group may be substituted with 1, 2 or 3 substituents Y wherein Y has the meaning as described hereinabove, with the proviso that R 6 represents a hydrogen atom, or a branched or unbranched alkyl group (C 1 - 5 ) which alkyl group may contain one or more heteroatoms from the group (O, N, S) or the -SO 2 - group and which alkyl group may be substituted with a
- pyrrolidinyl group or piperidinyl group which monocyclic, bicyclic or tricyclic alkyl or alkenyl group may contain an annelated phenyl group which annelated phenyl group may be substituted with 1 or 2 substituents Y, wherein Y has the meaning as described herein above, - R 7 represents branched or unbranched C ⁇ -3 alkyl,
- a lipase inhibiting compound for the use in the manufacture of a medicament for the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also for the treatment and/or prophylaxis of obesity in juvenile patients and/or drug induced obesity in juvenile as well as adolescent patients.
- combinations of the compounds of formula (Ilia) and/ or (lllb) together with lipase inhibiting compounds are highly valuable in providing medicaments for the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also in pediatric or juvenile obesity, and in drug induced obesity.
- At least one centre of chirality is present (at the C 4 position of the 4,5-dihydro-lH- pyrazole moiety) in the compounds of the formula (Ilia) and (lllb).
- the invention relates both to racemates, mixtures of diastereomers and the individual stereoisomers of the compounds having formula (Ilia) or (lllb).
- Particular compounds of interest of formula (Ilia) or (lllb) have the absolute stereoconfiguration at the C 4 position of the 4,5-dihydro-lH-pyrazole moiety as represented by the formulas (Ilia*) and (1Mb*):
- the invention also relates both to the E isomer, Z isomer and E/Z mixtures of compounds having formula (Ilia) or (lllb).
- the present invention is based on the surprising finding that the 4,5-diarylthiazole derivatives with CBi antagonistic activity of the formula (IV), pro-drugs thereof and salts thereof
- - R represents a hydrogen atom or a substituent X from the group branched or unbranched C ⁇ -3 -alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C ⁇ -2 )- amino, mono- or dialkyl (C ⁇ -2 )-amido, branched or unbranched (C ⁇ -3 )- alkoxycarbonyl, trifluoromethylsulfonyl, sulfamoyl, branched or unbranched alkyl(C ⁇ -3 )sulfonyl, carboxyl, cyano, carbamoyl, branched or unbranched dialkyl(C ⁇ -3 ) aminosulfonyl, branched or unbranched monoalkyl(C ⁇ -3 )- aminosulfonyl and acetyl,
- - Ri is a hydrogen atom or represents 1-4 substituents X, wherein X has the abovementioned meaning
- R 2 represents a phenyl, thienyl, pyridyl or pyrimidinyl group, which groups may be substituted with 1-4 substituents X, wherein X has the abovementioned meaning or R 2 represents naphtyl,
- R 3 represents a hydrogen atom or a branched or unbranched C MO alkyl or cycloalkyl-alkyl group or a phenyl, benzyl or phenethyl group which aromatic rings may be substituted with 1-5 substituents Z, which can be the same or different, from the group branched or unbranched C ⁇ -3 -alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C ⁇ -2 )-amino, mono- or dialkyl (C ⁇ -2 )-amido, branched or unbranched (C ⁇ -3 )-alkylsulfonyl, dimethylsulfamido, branched or unbranched C ⁇ -3 -alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, s
- R 4 represents branched or unbranched C ⁇ - ⁇ o alkyl or cycloalkyl-alkyl group, branched or unbranched C MO alkoxy, C 3 . 8 cycloalkyl, bicycloalkyl, C ⁇ -io tricycloalkyl, branched or unbranched C 3 - ⁇ o alkenyl, Cs- ⁇ cycloalkenyl, which groups may contain one or more heteroatoms from the group (O, N, S) and which groups may be substituted with a hydroxy group, 1-3 methyl groups, an ethyl group or 1-3 fluoro atoms, or R 4 represents a phenyl, benzyl or phenethyl group which aromatic rings may be substituted with 1-5 substituents Z, wherein Z has the abovementioned meaning, or R4 represents a pyridyl or thienyl group, or R 4 represents a group NR 5 Rf3 wherein R 5 and R 6 together
- R 3 and R - together with the nitrogen atom to which they are attached - form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having 4 to 10 ring atoms, which heterocyclic group contains one or more heteroatoms from the group (O, N, S) and which heterocyclic group may be substituted with a branched or unbranched C ⁇ -3 alkyl, hydroxy or trifluoromethyl group or a fluoro atom,
- a lipase inhibiting compound for the use in the manufacture of a medicament for the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also for the treatment and/or prophylaxis of obesity in juvenile patients and/or drug induced obesity in juvenile as well as adolescent patients.
- combinations of the compounds of formula (IV) together with lipase inhibiting compounds are highly valuable in providing medicaments for the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also in pediatric or juvenile obesity, and in drug induced obesity.
- the present invention is based on the surprising finding that 1 ,5-diaryl-1H-1,2,4-triazole-3-carboxamide derivatives with CBi antagonistic activity of the formula (V), as well as prodrugs, salts, and stereo-isomers thereof, are potent antagonists, agonists, inverse agonists or partial agonists of the cannabinoid CBi receptor:
- R and Ri independently represent a phenyl, naphtyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl or triazinyl group, which groups may be substituted with 1-4 substituents X, which can be the same or different, from the group branched or unbranched (C ⁇ -3 )-alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C ⁇ -2 )-amino, mono- or dialkyl (C ⁇ -2 )-amido, (C ⁇ -3 )-alkoxycarbonyl, trifluoromethylsulfonyl, sulfamoyl, (C ⁇ -3 )-alkylsul- fonyl, carboxyl, cyano, carbamoyl, (C ⁇ ⁇
- R 2 represents a hydrogen atom or a branched or unbranched C ⁇ -8 alkyl or C 1-8 cycloalkyl -alkyl group or a phenyl, benzyl or phenethyl group which aromatic rings may be substituted with 1 -4 substituents X, wherein X has the meaning as indicated above, or R 2 represents a pyridyl or thienyl group,
- R 3 represents branched or unbranched C ⁇ -8 alkyl, C ⁇ -8 alkoxy, C3- 8 cycloalkyl, Cs- ⁇ 0 bicycloalkyl, C ⁇ -1 0 tricycloalkyl, C3.
- R 3 represents a phenyl, benzyl or phenethyl group which aromatic rings may be substituted with 1-4 substituents X, wherein X has the meaning as indicated above, or R 3 represents a pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl or thienyl group which heteroaromatic rings may be substituted with 1-2 substituents X, wherein X has the meaning as indicated above, or R 3 represents a group NR R 5 wherein R_!
- a lipase inhibiting compound for the use in the manufacture of a medicament for the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also for the treatment and/or prophylaxis of obesity in juvenile patients and/or drug induced obesity in juvenile as well as adolescent patients.
- combinations of the compounds of formula (V) together with lipase inhibiting compounds are highly valuable in providing medicaments for the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also in pediatric or juvenile obesity, and in drug induced obesity.
- the compounds of formulas (I), (II), (III), (IV) and/or (V) used according to the invention are suitable also for general use in pediatric treatment and/or prophylaxis of other disorders than juvenile obesity and drug induced obesity in juvenile patients.
- the other disorders include those known from the literature for the concerned compounds with activity on the cannabis CBi-receptor, and e.g.
- the pediatric treatment and/or prophylaxis may also pertain to psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addiction, appetence, drug dependence and neurological disorders such as neurodege ⁇ erative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischemia, cerebral apoplexy, craniocerebral trauma, stroke, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelinisation related disorders, as well as for the pediatric treatment of pain disorders, including neuropathic pain disorders, and other diseases involving cannabinoid neurotransmission, including the pediatric treatment of septic shock, glaucoma, cancer, diabetes, emesis, nausea, asthma, respiratory diseases, gastrointestinal disorders, gastric ulcers, diarrho
- the affinity of the compounds of the formulas (I), (II), III), (IV) or (V) for cannabinoid CBi receptors can be determined as described in the WO 03/026647, WO 03/027076, WO 03/026648 or WO 03/078413, e.g. it can be determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabis CBi receptor is stably transfected in conjunction with [3H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand was performed by filtration over glass fibre filters. Radioactivity on the filter was measured by liquid scintillation counting.
- the cannabinoid CBi antagonistic activity of compounds of the formulas (I), (II), III), (IV) or (V) is also described in the WO 03/026647, WO 03/027076, WO 03/026648 or WO 03/078413, and was determined by functional studies using CHO cells in which human cannabinoid CB 1 receptors are stably expressed. Adenylyl cyclase was stimulated using forskolin and measured by quantifying the amount of accumulated cyclic AMP. Concomitant activation of CBi receptors by CBi receptor agonists (e.g.
- CP -55,940 or (R)-WIN-55,212-2) can attenuate the forskolin-induced accumulation of cAMP in a concentration-dependent manner.
- This CBi receptor -mediated response can be antagonized by CBi receptor antagonists such as the compounds used in the present invention.
- the cannabinoid CBi receptor antagonistic, agonistic or partial agonistic activity of compounds e.g. formula (V) of the invention can be also determined by functional studies using the human CBi receptor cloned in Chinese hamster ovary (CHO) cells according to the following protocol.
- CHO cells were grown in a DMEM culture medium, supplemented with 10% heat-inactivated fetal calf serum. Medium was aspirated and replaced by DM EM, without fetal calf serum, but containing [ 3 H]-Arachidonic acid and incubated overnight in a cell culture stove (5% CO 2 /95% air; 37 °C; water-saturated atmosphere).
- Cannabinoid receptor agonistic or partial agonistic activity of compounds of the invention can be determined according to published methods, such as assessment of in vivo cannabimimetic effects (Wiley, J. L. Jefferson et al., J. Pharmacol. Exp. Ther. 2001, 296, 1013).
- Cannabinoid receptor antagonists may behave as inverse agonists (Landsman, R. S. et al., Eur. J. Pharmacol. 1997, 334, R1-R2).
- the outstanding unique pharmacological profile of compounds with CBi-receptor activity and the formulas (I), (II), III), (IV) or (V) which are antagonists of the cannabis CBi-receptor, as well as prodrugs, tautomers and salts thereof, includes particularly high safety and tolerability also in combination with other drugs, in particular in combination with lipase inhibiting compounds according to the present invention.
- the CBi antagonistic compounds of the formulas (I), (II), III), (IV) or (V) in combination with lipase inhibiting compounds are particularly suitable also in patient groups with enhanced need of safety and tolerability, in particular such as juvenile patients and/or patients subject to long term treatment, e.g. in drug induced obesity.
- CBi antagonistic compounds of the formulas (I), (II), III), (IV) or (V) in combination with lipase inhibiting compounds is advantageous in the treatment and/or prophylaxis of obesity in those patient populations where a single treatment is not sufficiently effective and a combination treatment and/or prophylaxis involving different medical or metabolic mechanisms is desired or required for achieving and stabilizing a defined degree of weight loss.
- combination of CBi antagonistic compounds of the formulas (I), (II), III), (IV) or (V) in combination with lipase inhibiting compounds according to the present invention is expected to be very is advantageous in the treatment and/or prophylaxis of obesity in general, e.g. of obesity in adolescent patients of any age, and particularly also in pediatric or juvenile obesity, and in drug induced obesity.
- the CBi receptor modulating activity of the compounds of the formulas (I), (II), III), (IV) or (V) of the invention makes them particularly useful in the treatment of obesity, juvenile obesity and drug induced obesity, when used in combination with lipase inhibitors.
- lipase inhibiting compounds which can be used in such combination preparations are (but not restricted to) the synthetic lipase inhibitor oriistat, panclicins, lipase inhibitors isolated from micro organisms such as lipstatin (from Streptomyces toxytricini), ebelactone B (from Streptomyces aburaviensis), synthetic derivatives of these compounds, 2-oxy-4H- 3,1-benzoxazin-4-one derivatives like ATL-962 and structurally related compounds, 2-amino-4H-3,1-benzoxazin-4-one derivatives, as well as extracts of plants known to possess lipase inhibitory activity, for instance extracts of Alpinia officinarum Hance or compounds isolated from such extracts like 3- methylethergalangin (from A. officinarum).
- the lipase inhibiting compound may also be a lipase inhibiting polymer.
- Lipase inhibiting compounds used in the combinations according to the present invention may be any lipase inhibiting compound suitable for pharmaceutical use, e.g. in particular inhibitors of pancreatic lipases.
- Lipases are key enzymes in the digestive system which break down tri- and diglycerides, which are too large to be absorbed by the small intestine into fatty acids which can be absorbed. Since lipases are responsible for the hydrolysis of fat, a consequence of their inhibition is a reduction in fat hydrolysis and absorption. Therefore, inhibition of lipases results in a reduction in the absorption of fat.
- the lipase inhibiting compound is preferably the synthetic lipase inhibitor oriistat and structurally related compounds, 2-oxy-4H-3,1-benzoxazin-4-one derivatives like ATL-962 and structurally related compounds, 2-amino-4H-3,1-benzoxazin-4-one derivatives, lipase inhibitors isolated from micro organisms such as lipstatin, ebelactone B, or synthetic derivatives of these compounds, however may also be a lipase inhibiting polymer. Most preferred are oriistat, panclicins, ATL-962 and lipstatin.
- Oriistat tetrahydrolipstatin
- lipstatin are described in the US-patent US 4,598,089 and its European equivalent EP 0 129 748 B1 in more detail.
- the compounds are 2-hexyl-3-hydroxy-hexadecanoic acid lactone derivatives with the chemical names (2S,3S,5S,7Z,10Z)-5-((S)-2-formamido-4-methylvaleryloxy)-2- hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone (lipstatin) and (2S,3S,5S)-5- ((S)-2-4-methylvaleryloxy)-2-heyl-3-hydroxy-hexadecanoic acid lactone (tetrahydrolipstatin).
- the compounds are known to be inhibitors of pancreas lipase which can be used for the prevention of treatment of obesity and hyperiipaemia, for which purpose they can be formulated as medicaments or incorporated into industrially prepared foodstuffs. Inhibition of pancreas lipase prevents the hydrolysis of dietary fats to give absorbable free fatty acids and monoglycerides, so that the fats are excreted unchanged.
- IC50's for lipstatin and tetrahydrolipstatin for inhibition of hydrolysis of triolein by porcine pancrease lipase are 0.07 and 0.18 mcg/ml, respectively.
- panclicins are suitable lipase inhibitors which are structurally related to oriistat and/or lipstatin and which are known as panclicins.
- panclicines are derived from oriistat and contain a 4-ring lactone (Mutoh M; Nakada N; Matsukima S; Ohshima S; Yoshinari K; Watanabe J Location: Kanagawa, Japan Issue Date: 19-JAN-1995 Journal: J.Antibiot., 47, No. 12, 1369-75, 1994).
- panclicins A, B, C, D and E structural analogs of tetrahydrolipstatin (THL), dose-dependently inhibited hydrolysis of triolein of fatty acids by porcine pancreatic lipase, with IC50 values of 2.9, 2.6, 0.62, 0.66 and 0.89 microM, respectively.
- the inhibitory activity of panclicins A and B (alanine moiety in place of leucine in THL) was 2-3-fold weaker than that of THL; in contrast, the inhibitory activity of panclicins C, D and E (glycine moiety in place of leucine in THL) was 2-fold stronger than that of THL.
- Panclicins A, B, C, D and E also potently inhibited plasma lipases with IC50 values of 1.0, 1.2, 0.29, 0.25 and 0,15 microM, respectively.
- Panclicins A and B inhibited plasma lipases with the same potency as THL, while panclicins C, D and E had a 3-6-fold greater inhibitory activity than THL.
- Panclicins A, B, C, D and E inhibited bacterial and fungal lipases with profiles similar to those for porcine pancreatic lipase.
- Panclicins inhibited pancreatic lipase irreversibly, but less irreversibly than THL.
- Panclicins A, B, C, D and E irreversibly inhibit pancreatic lipase.
- Ebelactone B is described in the US -patent US 4,358,602 and its German equivalent DE 3 109 335 C1 .
- Ebelactone A and ebelactone B belong to a group of compounds that exhibit activity to enhance the cell mediated immune response in living animals and they also inhibit inflammations in living animals. Thus they may be used in the immunological treatment of tumours and for enhancing anti- tumour agents such as bleomycins.
- the compounds have anti-esterase activity and anti-formylmethionine aminopeptidase activity.
- mice of these compounds at a dosage of 0.781-50 mg/kg (i.p.) or 0.5 mg/kg (per os) enhances the development of DTH response and the compounds show a potentiating effect on cell-mediated immunity.
- Ebelactone B reduces carragheenin-induced swelling in mice.
- the lipase inhibitors administered in combination with the CBi antagonistic compounds to a patient for treating obesity may be also a polymer that has been substituted with or comprises one or more groups which can inhibit a lipase.
- Such lipase inhibiting polymers are described in the US patents US 6572850, US 6558657, US 6352692, US 6267952 and in the international patent application WO 99/34786.
- the lipase inhibiting group can be a "suicide substrate" which inhibits the activity of the lipase by forming a covalent bond with the enzyme either at the active site or elsewhere.
- the lipase inhibiting group is an isosteric inhibitor of the enzyme.
- the lipase inhibiting group inactivates a lipase such as gastric, pancreatic and lingual lipases. Inactivation can result by forming a covalent bond such that the enzyme is inactive.
- the covalent bond can be formed with an amino acid residue at or near the active site of the enzyme, or at a residue which is distant from the active site provided that the formation of the covalent bond results in inhibition of the enzyme activity.
- Lipases contain a catalytic triad which is responsible for the hydrolysis of lipids into fatty acids. The catalytic triad consists of a serine, aspartate and histidine amino acid residues.
- serine protease inhibitors that can be covalently linked to a polymer are preferred lipase inhibiting groups.
- a covalent bond can be formed between the lipase inhibiting group and a hydroxyl at or the catalytic site of the enzyme.
- a covalent bond can be formed with serine.
- Inactivation can also result from a lipase inhibiting group forming a covalent bond with an amino acid, for example cysteine, which is at some distance from the active site.
- non-covalent interaction between the lipase inhibiting group and the enzyme can also result in inactivation of the enzyme.
- the lipase inhibiting group can be an isostere of a fatty acid, which can interact non-covalently with the catalytic site of the lipase.
- the lipase inhibiting group can compete for lipase hydrolysis with natural triglycerides.
- the polymers can be aliphatic, alicyclic or aromatic or synthetic or naturally occurring. However, aliphatic and alicyclic synthetic polymers are preferred. Furthermore, the polymer can be hydrophobic, hydrophilic or copolymers of hydrophobic and/or hydrophilic monomers. The polymer can be non-ionic (e.g., neutral), anionic or cationic, in whole or in part. Furthermore, the polymers can be manufactured from olefinic or ethylenic monomers (such as vinylalcohol) or condensation polymers.
- the polymers can be a poly vinylalcohol, polyvinylamine, poly-N-alkylvinylamine, polyallylamine, poly-N-alkylallylamine, polyalkylenimine, polyethylene, polypropylene, polyether, polyethylene oxide, polyamide, polyacrylic acid, polyalkylacrylate, polyacrylamide, polymethacrylic acid, polyalkylmethacrylate, polymethacrylamide, poly-N-alkylacrylamide, poly-N- alkylmethacrylamide, polystyrene, vinylnaphthalene, ethylvinyl benzene, aminostyrene, vinylbi phenyl, vinylanisole, vinylimidazolyl, vinylpyridinyl, dimethylaminomethylstyrene, trimethylammoniumethylmethacrylate, trimethylammoniumethylacrylate, carbohydrate, protein and substituted derivatives of the above (e.g., fluorinated monomers thereof) and copoly
- R1 may be 7-22C alkyl; 2-4C alkyl substituted by 4-20C alkoxy, 6-10C aryl, 6-10C aryloxy or (4-12C) alkoxy-(2-4C) alkoxy (where aryl can be substituted by one or more of halogen, 1-4C alkyl, 1-4C alkoxy, NO2 or CF3); 7-20C alkenyl; or phenyl substituted by 6-12C alkyl or by phenoxy; and R2 to R5 each may be H, halogen, NO2, 1 -4C alkyl, 1-4C alkoxy, CF3 or OCF3; or (6-10C) aryl-(1-4C) alkoxy, 6-10C aryloxy, 6-10C aryl, 3-8C
- 5-hydrocarbyloxy-3-phenyl-1,3,4-oxadiazol-2-ones are described to have pharmacological properties as anorectic, antidiabetic, hypotensive or cardiant, with mechanism of action as pancreatic lipase inhibitors.
- 5- dodecyloxy-3-(4-trifluoromethoxy-phenyl)-3H-(1,3,4)-oxadiazol-2-one had IC50 0.03 microM for inhibition of porcine pancreatic lipase.
- these 5- hydrocarbyloxy-3-phenyl-1 ,3,4-oxadiazol-2-ones may be used as medicaments, especially for the treatment of obesity.
- the 5- hydrocarbyloxy-3-phenyl-1 ,3,4-oxadiazol-2-ones inhibit the resorption of the fat content of foods and thus reduce fat uptake and body weight (or prevent increase in body weight). Furthermore, the 5-hydrocarbyloxy-3-phenyl-1 ,3,4- oxadiazol-2-ones are reported to also have a beneficial effect in the treatment of metabolic disorders (e.g. diabetes) or cardiovascular disorders (e.g. hypertension and cardiac infarction).
- metabolic disorders e.g. diabetes
- cardiovascular disorders e.g. hypertension and cardiac infarction.
- the lipase inhibiting compounds of formula (A) are described in more detail in the WO 03/072555 and can be obtained according to known methods.
- R1 may be 1-6C alkyl; 3-9C-cycloalkyl, both groups optionally may be substituted by phenyl, 1-4C alkoxy, S-1-4C alkyl, N(1-4C-alkyl)2; and phenyl optionally may be also substituted by halogen, 1-4C alky, 1-4C-alkyloxy, nitro or CF3; and R2 to R5 each may be independently H, halogen, NO2, 1-4C alkyl, 1-9C alkoxy which is substituted by F, 6-10C-aryl, amino or1-4C alkyl amino; 6-10C-aryl-1 ⁇ C-alkyloxy, 6-10C-aryloxy, 6-10C-aryl, 6-10C-aryloxy-1-4C- alkyl, 3-8C cycloalkyl or 0(3-8 cycloalky), which may optionally be substituted by halogen, CF3, 1-4 alkyloxy or 1-4C alkyl; SO2-NH-(
- X is O(1 -6C alkyl), NH(1-6C alkyl), NH(3-8C cycloalkyl or N(1-6C alkyl)2 and N(1-6C alkyl)2 may be also pyrrolidino, piperidino, morpholino, thiomorpholino or piperazino, which optionally substituted by 1 -4C alkyl, benzyl, 6-10C aryl, CO-(1 -4 alkyl), CO-(6-10 aryl), CO-O-(1-4C alkyl), SO2-(1-4C alkyl) or SO2-(6-10C aryl);
- R6 is H, 1-4C alkyl or 6-10C-aryl-1-4C-alkyl, wherein aryl may be substitutet by halogen, CF3, 1-8C alkyloxy or 1- C alkyl;
- A is a single bond, COn, SOn or CONH;
- n is 1 oder2:
- R7 is H
- the lipase inhibiting compounds of formula (A) are described in more detail in the WO 03/072098 and can be obtained according to known methods.
- a suitable synthesis for the lipase inhibiting compounds of formula (A) is described also in the international patent application WO 03/072098.
- the whole content of the international patent application WO 03/072098 is incorporated by reference into the present application regarding the disclosure of lipase inhibitors of formula (A).
- R1a is (i) a C10-30 branched or unbranched alkyl , optionally substituted by one or more independently of C3-6 cycloalkyl, C3-6 cycloalkenyl, aryl, heteroaryl, reduced heteroaryl, -C(O)R13, -CO2R13, -SOR13, - SO2R13, -NR13R14, -OR13, -SR13, -C(O)NR13R14, -NR14C(O)R13, halogen, cyano, and nitro and/or optionally interrupted by one or more oxygen atoms with the proviso that any hetero atom in R1a must be separated from the exocyclic oxygen atom (or from any other heteroatom) by at least two carbon atoms; (ii) C2-25 alkenyl, C2-25 alkynyl, C3-6 cycloalkenyl, aryl-C2-25 alkenyl, heteroaryl-C2-25 alken
- R8a, R9a, R10a and R11a are each independently hydrogen, halo, hydroxy, amino, nitro, cyano, thiol, C1 -10 alkyl,
- R15 and R16 each independently represent hydrogen or C1-10 alkyl with the proviso that when R8a, R9a, R10a, and R11a are H, R1a is not CH2CH2CI or
- ATL-962 has the chemical name 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one. Preclinical studies showed that ATL-962 had similar efficacy to oriistat and no toxicity was observed. Clinical data for these compounds is also available in the public domain, e.g. resulting from clinical studies with ATL-962 in obesity.
- 55% of subjects who received ATL-962 demonstrated a 3-fold or greater increase in fat excretion and 27% of subjects demonstrated a 7-fold or greater increase.
- Adverse events and their frequency were similar between ATL-962 and placebo and were mainly gastrointestinal, with the predominant event being oily stool.
- the lipase inhibiting compounds of formula (B) like ATL-962 and structurally related compounds are described in more detail in the US patent US 6,624,161 and its corresponding international patent application WO 00/040569, and can be obtained according to known methods.
- a suitable synthesis for the lipase inhibiting compounds of formula (B) is described also in the US 6,624,161 and international patent application WO 00/040569.
- the whole content of the US 6,624,161 and international patent application WO 00/040569 is incorporated by reference into the present application regarding the disclosure of lipase inhibitors of formula (B).
- the whole content of the international patent application WO 00/040247 is also incorporated by reference into the present application regarding the disclosure of lipase inhibitors described therein, with related 2- amino-4H-3,1-benzoxazin-4-one compound structure.
- the CBi antagonistic compound of the formulas (I), (II), III), (IV) or (V), or a prodrug, tautomer or salt thereof, and the lipase inhibiting compound used according to the invention can be brought into forms suitable for pediatric treatment and/or prophylaxis of the diseases indicated above, and in particular of obesity, e.g. for adolescent or pediatric administration, as well as for the administration in treating drug induced obesity by means of usual processes using pharmaceutical excipients, auxiliary substances and/or liquid or solid carrier materials.
- the CBi antagonistic compound and/or the lipase inhibiting compounds may be contained together with (conventional) pharmaceutical excipients, adjuvants and/or auxiliaries in pharmaceutical preparations such as tablets, capsules, suppositories or solutions.
- pharmaceutical preparations such as tablets, capsules, suppositories or solutions.
- These pharmaceutical preparations may be prepared according to known methods, using conventional solid or liquid vehicles such as lactose, starch or talc, or liquid paraffins and/or using (conventional) pharmaceutical excipients, adjuvants and/or auxiliaries, such as tablet disintegrating agents, solubilisers or preservatives.
- the invention also pertains to a pharmaceutical composition containing at least one compound with CBi-receptor activity of the formulas (I), (II), III), (IV) or (V), or a prodrug, tautomer or salt thereof, in combination with at least one lipase inhibiting compound.
- a preferred pharmaceutical composition contains at least one compound of the formulas (I), (II), III), (IV) or (V) as defined above in combination with at least one lipase inhibiting compound as combined active components.
- a further pharmaceutical composition according to the invention contains as active components at least one compound with CBi-receptor activity having the formula (I), (II), III), (IV) or (V) as defined above, preferably the CB1 antagonistic compound , or a prodrug, tautomer or salt thereof, and at least one lipase inhibiting compound for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients.
- compositions according to the invention are characterized in that the at least one compound with CBi- receptor activity having the formula (I), (II), III), (IV) or (V) as defined above, preferably the CBi antagonist, or the prodrug, tautomer or salt thereof, and the at least one lipase inhibiting compound each are present in an amount effectively suited for the treatment and/or prophylaxis of obesity in a juvenile patient in need of such treating.
- the CBi antagonistic compound in particular the CBi antagonistic compound of the formulas (I), (II), III), (IV) or (V), and the lipase inhibiting compound are each present in the pharmaceutical composition in an amount effectively suited for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients in need of such treating.
- the CBi antagonistic compound preferably the CBi antagonistic having the formula (I), (II), III), (IV) or (V), or the prodrug, tautomer or salt thereof, is used preferably in combination with at least one lipase inhibiting compound selected from the group of lipase inhibiting polymers, oriistat, panclicins, ATL-962 and lipstatin.
- the invention also pertains to a pharmaceutical product containing as a medicament a CBi antagonistic compound, preferably the CBi antagonistic compound having one of the formulas (I), (II), III), (IV) or (V) as defined above, or a prodrug, tautomer or salt thereof, and a leaflet indicating that said CBi antagonistic compound may be administered in combination with a lipase inhibiting compound for simultaneous, separate or step-wise administration in the treatment and/or prophylaxis of obesity.
- a CBi antagonistic compound preferably the CBi antagonistic compound having one of the formulas (I), (II), III), (IV) or (V) as defined above, or a prodrug, tautomer or salt thereof, and a leaflet indicating that said CBi antagonistic compound may be administered in combination with a lipase inhibiting compound for simultaneous, separate or step-wise administration in the treatment and/or prophylaxis of obesity.
- the invention also includes a method of treatment and/or prophylaxis of obesity, e.g. in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients, characterized in that a CBi antagonistic compound, in particular a compound of the formula (I), (II), III), (IV) or (V), which is an antagonist of the cannabis CBi- receptor, or a prodrug, tautomer or salt thereof, is administered in combination with at least one lipase inhibiting compound to a patient in need of such treating.
- a CBi antagonistic compound in particular a compound of the formula (I), (II), III), (IV) or (V), which is an antagonist of the cannabis CBi- receptor, or a prodrug, tautomer or salt thereof, is administered in combination with at least one lipase inhibiting compound to a patient in need of such treating.
- a CBi antagonistic compound which is a compound of one of the formulas (I), (II), III), (IV) or (V)as defined above, or a prodrug, tautomer or salt thereof, is administered in combination with at least one lipase inhibiting compound.
- the method of treatment and/or prophylaxis of obesity according to the present invention may be directed to obesity in adolescent or in juvenile patients and/or to drug induced obesity in juvenile as well as adolescent patients.
- the method of treatment and/or prophylaxis is characterized in that the treating is directed to obesity in juvenile patients.
- the method of treatment and/or prophylaxis is characterized in that the treating is directed to drug induced obesity in juvenile or adolescent patients.
- the CBi antagonistic compound preferably the CBi antagonistic compound having one of the formulas (I), (II), III), (IV) or (V) as defined above, or a prodrug, tautomer or salt thereof, is administered preferably in combination with at least one lipase inhibiting compound selected from the group of lipase inhibiting polymers, oriistat, panclicins, ATL-962 and lipstatin.
- the CBi antagonistic compound preferably the CB1 antagonistic compound having one of the formulas (I), (II), III), (IV) or (V) as defined above, or a prodrug, tautomer or salt thereof, is administered in combination with the lipase inhibiting compound by simultaneous, separate or step- wise administration route.
- the compounds used in the combinations or compositions according to the present invention each are preferably administered to a patient in need thereof and in a quantity sufficient to prevent and/or treat the symptoms of the condition, disorder or disease, e.g. obesity.
- the administration of a compound or composition has a dosage regime which will ultimately be determined by the attending physician and will take into consideration such factors such as the compound being used, animal type, age, weight, severity of symptoms, method of administration, adverse reactions and/or other contraindications.
- Specific defined dosage ranges can be determined by standard design clinical trials with patient progress and recovery being fully monitored. Such trials may use an escalating dose design using a low percentage of the maximum tolerated dose in animals as the starting dose in man.
- the physiologically acceptable compounds used in the combinations or compositions according to the present invention each are will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 2000 mg, preferably between 30 mg and 1000 mg, e.g. between 10 and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 50 mg, e.g. between 1 and 25 mg of the compound of the formula (I) or a physiologically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
- the compounds will be administered for a period of continuous therapy, for example for a week or more.
- a part of the oral dose for an adult patient is administered, e.g. 1 fifth to 1 half of the oral dose described before for an adult patient.
- the method of treatment and/or prophylaxis is directed to the treating of obesity in juvenile patients.
- the method of treatment and/or prophylaxis is directed to the treating of drug induced obesity in juvenile or adolescent patients. This drug induced obesity may be in particular caused by drugs like atypical antipsychotics.
- the method of treatment and/or prophylaxis is directed to the treating of obesity in juvenile patients.
- Cannabinoid antagonists in combination with lipase inhibitors are particulariy suitable for the treatment of Childhood Obesity and related Comorbidities as for example Type 2 Diabetes.
- Childhood Obesity and related Comorbidities as for example Type 2 Diabetes.
- the prevalence of overweight in children grew from 5% to 11% (Sorof and Daniels 2002).
- childhood obesity has tripled in the past 20 years (Spurgeon 2002).
- Type 2 diabetes in children is part of the insulin resistance syndrome (Rosenbloom 2002) that includes hypertension, dyslipidemia and other atherosclerosis risk factors, and hyperandrogenism seen as premature adrenarche and polycystic ovary syndrome.
- Other outcomes related to childhood obesity include left ventricular hypertrophy, nonalcoholic steatohepatitis, obstructive sleep apnea, orthopedic problems, and severe psychosocial problems.
- CBi antagonists used according to the present invention in combination with lipase inhibitors offer a unique opportunity for the treatment of obesity by interacting with these "driving forces". They are superior to current medical treatments and especially suited for adolescent as well as pediatric treatment because of their outstanding safety profile and/or tolerability and surprisingly beneficial combination effects. Besides efficacy, the treatment of obesity, especially the treatment of childhood obesity, dictated by safety. Obesity in childhood is a medical condition that is likely to require long-term management.
- CBi antagonists used according to the present invention in combination with lipase inhibitors are suggested to be superior to current standard medications, and these CBi antagonists in combination with lipase inhibitors will be especially suited for the treatment and prevention of obesity in adolescents and in childhood obesity and related co- morbidities.
- the method of treatment and/or prophylaxis is directed to the treating of drug induced obesity in juvenile or adolescent patients.
- Drug induced weight gain is also of major concern and subject to high medical need of improved treatments.
- the CBi antagonists in combination with lipase inhibitors according to the present invention are suggested to be superior to current standard medications, and these CBi antagonists in combination with lipase inhibitors will be especially suited for the treatment and prevention of drug induced obesity in juvenile as well as in adolescent patients.
- drug induced weight gain it is reported by Zimmermann, U., T. Kraus, et al.
- the beneficial pharmacological effects of the combination of a CBi antagonist with a lipase inhibitor according to the invention can be shown by standard experimental animal models by measuring the influence of the administered combination of a CBi antagonist with a lipase inhibitor on the driving and characteristic parameters associated with obesity.
- the rats will have unlimited access to feed for two 2.5h periods per day, during the dark phase of a reversed 12h/12h light cycle, e.g. lights are put on at 21.15h and put off at 09.15h.
- the rats will be offered a high fat, high sucrose diet (Western diet).
- the lipase inhibitor will be dosed immediately before the rats are fed.
- the CBi antagonist will be dosed 1h before the lipase inhibitor is administered.
- the following daily dosing schedule is applicable for a given period of e.g. days, weeks or months:
- the CBi antagonist in particular the CBi antagonisic compound of formula (I) as defined above, or a vehicle dose is administered (po) in the morning at ca. 07.45 to 08.00 h.
- the lipase inhibitor e.g. in particular oriistat, or a vehicle dose is administered (po) ca. 08.45 to 09.00 h.
- the rats are set to ad- libitum feed from 09.15 to 11.45h, followed by feed removal from about 11.45 to 14.45 h.
- Another dose of lipase inhibitor e.g.
- oriistat in particular oriistat, or vehicle (Labrasol) dose is administered (po) in the afternoon at about 14.15 to 14.30h, followed by ad-libitum feed from 14.45 to 17.15 h. Thereafter, the rats are set to feed deprivation from 17.15 - 09.15 h.
- the experimental protocol results will compare daily food intake and body weight gain as indicators for the effects of the combination treatment on obesity during the experimental phase.
- biochemical parameters may be measured at slaughter of the rats.
- Control group The rats receive only vehicle according to the protocol to simulate administration (placebo group).
- CBi group The rats receive a CBi antagonist in a vehicle.
- LI group The rats receive as lipase inhibitor ("LI”) e.g. the compound oriistat in a vehicle.
- CBi+LI group (combination group): The rats receive a CBi antagonist in a vehicle and as lipase inhibitor ("LI”) e.g. the compound oriistat in a vehicle.
- the 1 H-1 ,2,4-triazole-carboxamide derivatives of formula (V), which are potent cannabinoid-CBi receptor agonists, partial agonists, inverse agonists or antagonists, useful for the treatment of psychiatric and neurological disorders, as well as other diseases involving cannabinoid-CBi neurotransmission, are defined above in the specification.
- a group of four 1,5-diaryl-1 H-1 ,2,4-triazole-3-carboxamide derivatives in which the amide N-atom is part of an unsubstituted piperidinyl or morpholinyl group is described by D. Clerin and J.P. Fleury in Bull. Soc. Chim. Fr., 1974, 1-2, Pt.2, 211-217.
- 1-(4-Methylphenyl)-5-phenyl-N-(2-pyridyl)-1 H-1 ,2,4-triazole-3-carboxamide is described by M. H. Elnagdi et al. in Heteroatom Chem., 1995, 6, 589-592.
- Suitable synthetic routes for the compounds of formula (V) used in the invention are the following:
- Step 1 Ester hydrolysis of a compound having formula (S-ll) wherein R. 3 represents a branched or unbranched (C ⁇ )-alkyl group or a benzyl group,
- R and Ri have the meanings as described above.
- Step 2 Reaction of a compound having formula (S-lll) with a compound having formula R 2 R 3 NH wherein R 2 and R 3 have the meanings as described above via activating and coupling methods such as formation of an active ester, or in the presence of a coupling reagent such as DCC, HBTU, BOP, CIP (2-chloro-1,3- dimethylimidazolinium hexafluorophosphate) or PyAOP (7-azabenzotriazol-1- yloxytris(pyrrolidino)phosphonium hexafluorophosphate).
- a coupling reagent such as DCC, HBTU, BOP, CIP (2-chloro-1,3- dimethylimidazolinium hexafluorophosphate) or PyAOP (7-azabenzotriazol-1- yloxytris(pyrrolidino)phosphonium hexafluorophosphate.
- a compound having formula (S-lll) is reacted with a halogenating agent such as thionyl chloride (SOCI 2 ) or oxalyl chloride. This reaction yields the corresponding carbonyl chloride (acid chloride) (S-IV).
- a halogenating agent such as thionyl chloride (SOCI 2 ) or oxalyl chloride.
- a compound having formula (S-ll) is reacted in an amidation reaction with a compound having formula R 2 R 3 NH wherein R 2 and R 3 have the meanings as described hereinabove to give a 1H-1 ,2,4-triazole derivative having formula (V).
- amidation reactions can be promoted by the use of trimethylaluminum AI(CH 3 ) 3 (For more information on aluminum-mediated conversion of esters to amides, see: J. I. Levin, E. Turos, S. M. Weinreb, Synth Commun. (1982), 12, 989-993.)
- Part B To a stirred suspension of 2,4-dichloroaniline (19.44 gram, 0.12 mol) in concentrated HCI (25 mL) and acetic acid ( 75 mL) at 0 °C is added a solution of NaNO 2 (9.0 gram, 0.13 mol) in water (50 mL) and the resulting solution is stirred for 15 minutes. A solution of dimethyl 2-(4-chlorobenzoylamino)-malonate (28.55 gram, 0.10 mol) in acetone (200 mL) is slowly added while keeping the temperature below 0 °C.
- Part C To a stirred suspension of methyl 5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-1 H-1,2,4-triazole-3-carboxylate (11.3 gram, 0.0295 mol) in methanol (100 mL) is added KOH (45 % aqueous solution, 7.5 mL) and the resulting mixture is heated at reflux temperature for 4 hours. The mixture is concentrated in vacuo and water (150 mL) and concentrated HCI are added.
- Part D To a stirred solution of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H- 1 ,2,4-triazole-3-carboxylic acid (1.48 gram, 4.0 mmol) in acetonitrile (20 mL) is successively added diisopropylethylamine (DIPEA) (1.5 mL, 2.1 molar equivalent), O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) (1.66 gram, 1.1 molar equivalent) and 1-aminopiperidine (0.44 gram, 1.1 molar equivalent).
- DIPEA diisopropylethylamine
- HBTU O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate
- 1-aminopiperidine (0.44
- the purified material is treated with ethanolic HCI (1 M solution) to give 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-1H-1,2,4-triazole-3- carboxamide hydrochloride (1.50 gram, 77 % yield). Melting point: 238-240 °C (decomposition). 1 H-NMR (400 MHz, DMSO-d 6 ): .
- Part B To a stirred solution of 1-(chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1 ,2,4- triazole-3-carboxylic acid (0.37 g, 1.00 mmol) in dichloromethane (10 mL) is added oxalyl chloride (0.254 g, 2.00 mmol). The resulting mixture is concentrated in vacuo to give crude 1-(chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1 ,2,4-triazole- 3-carbonyl chloride.
- Part C The crude 1-(chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1 ,2,4-triazole-3- carbonyl chloride is dissolved in tetrahydrofuran (THF) (10 mL). 2,3-Dihydro-1 H- inden-2-ylamine (0.40 g, 3.00 mmol) is added and the resulting solution is stirred for 42 hours at 25 °C.
- THF tetrahydrofuran
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0415851-2A BRPI0415851A (en) | 2003-10-24 | 2004-10-22 | medical uses of compounds exhibiting cb1 antagonistic activity and combination treatment involving said compounds |
JP2006536096A JP2007513872A (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds exhibiting CB1 antagonism and combination therapy with said compounds |
CA002543338A CA2543338A1 (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
MXPA06004434A MXPA06004434A (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing cb1. |
AU2004283056A AU2004283056A1 (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds |
EP04817279A EP1753413A2 (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing cb sb 1/sb -antagonistic activity and combination treatment involving said compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03103961 | 2003-10-24 | ||
EP03103961.3 | 2003-10-24 | ||
EP03103967 | 2003-10-27 | ||
EP03103967.0 | 2003-10-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005039550A2 true WO2005039550A2 (en) | 2005-05-06 |
WO2005039550A3 WO2005039550A3 (en) | 2007-03-22 |
Family
ID=34524748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/052639 WO2005039550A2 (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1753413A2 (en) |
JP (1) | JP2007513872A (en) |
AU (1) | AU2004283056A1 (en) |
BR (1) | BRPI0415851A (en) |
CA (1) | CA2543338A1 (en) |
MX (1) | MXPA06004434A (en) |
RU (1) | RU2006117627A (en) |
WO (1) | WO2005039550A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7348456B2 (en) | 2002-12-19 | 2008-03-25 | Merck & Co., Inc. | Substituted amides |
EP1680106B1 (en) * | 2003-10-24 | 2009-08-05 | Solvay Pharmaceuticals GmbH | Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7777036B2 (en) | 2004-09-20 | 2010-08-17 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
US8026360B2 (en) | 2004-09-20 | 2011-09-27 | Xenon Pharmaceuticals Inc. | Substituted pyridazines as stearoyl-CoA desaturase inhibitors |
US8039497B2 (en) | 2006-11-10 | 2011-10-18 | Laboratorios Del Dr. Esteve, S.A. | 1,2,4-triazole derivatives as sigma receptor inhibitors |
US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0377457A1 (en) * | 1989-01-05 | 1990-07-11 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole compounds, processes for the preparation thereof, and pharmaceutical composition comprising the same |
WO1996003392A1 (en) * | 1994-07-27 | 1996-02-08 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
WO1996003388A1 (en) * | 1994-07-28 | 1996-02-08 | G.D. Searle & Co. | 1,2-substituted imidazolyl compounds for the treatment of inflammation |
WO2000069848A1 (en) * | 1999-05-14 | 2000-11-23 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
WO2002076949A1 (en) * | 2001-03-22 | 2002-10-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2003026648A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
WO2003026647A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2003027076A2 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity |
WO2003040107A1 (en) * | 2001-09-24 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
WO2003039451A2 (en) * | 2001-11-08 | 2003-05-15 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole pyridazinones as adenosine antagonists |
WO2003043619A1 (en) * | 2001-11-23 | 2003-05-30 | Astrazeneca Ab | New use for the treatment of gastroesophageal reflux disease |
WO2003063781A2 (en) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
WO2003078413A1 (en) * | 2002-03-18 | 2003-09-25 | Solvay Pharmaceuticals B.V. | Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
WO2004012727A1 (en) * | 2002-08-06 | 2004-02-12 | Abbott Laboratories | Compositions comprising polysaturated fatty acid (pufas) for the control of appetite and body weight management |
WO2004026301A1 (en) * | 2002-09-19 | 2004-04-01 | Solvay Pharmaceuticals B.V. | 1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
WO2004058255A1 (en) * | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | 4, 5-diarylthiazole derivatives as cb-1 ligands |
-
2004
- 2004-10-22 WO PCT/EP2004/052639 patent/WO2005039550A2/en active Application Filing
- 2004-10-22 MX MXPA06004434A patent/MXPA06004434A/en not_active Application Discontinuation
- 2004-10-22 AU AU2004283056A patent/AU2004283056A1/en not_active Abandoned
- 2004-10-22 JP JP2006536096A patent/JP2007513872A/en not_active Withdrawn
- 2004-10-22 EP EP04817279A patent/EP1753413A2/en not_active Withdrawn
- 2004-10-22 BR BRPI0415851-2A patent/BRPI0415851A/en not_active IP Right Cessation
- 2004-10-22 CA CA002543338A patent/CA2543338A1/en not_active Abandoned
- 2004-10-22 RU RU2006117627/04A patent/RU2006117627A/en not_active Application Discontinuation
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0377457A1 (en) * | 1989-01-05 | 1990-07-11 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole compounds, processes for the preparation thereof, and pharmaceutical composition comprising the same |
WO1996003392A1 (en) * | 1994-07-27 | 1996-02-08 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
WO1996003388A1 (en) * | 1994-07-28 | 1996-02-08 | G.D. Searle & Co. | 1,2-substituted imidazolyl compounds for the treatment of inflammation |
WO2000069848A1 (en) * | 1999-05-14 | 2000-11-23 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
WO2002076949A1 (en) * | 2001-03-22 | 2002-10-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2003026648A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
WO2003026647A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2003027076A2 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity |
WO2003040107A1 (en) * | 2001-09-24 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
WO2003039451A2 (en) * | 2001-11-08 | 2003-05-15 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole pyridazinones as adenosine antagonists |
WO2003043619A1 (en) * | 2001-11-23 | 2003-05-30 | Astrazeneca Ab | New use for the treatment of gastroesophageal reflux disease |
WO2003063781A2 (en) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
WO2003078413A1 (en) * | 2002-03-18 | 2003-09-25 | Solvay Pharmaceuticals B.V. | Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
WO2004012727A1 (en) * | 2002-08-06 | 2004-02-12 | Abbott Laboratories | Compositions comprising polysaturated fatty acid (pufas) for the control of appetite and body weight management |
WO2004026301A1 (en) * | 2002-09-19 | 2004-04-01 | Solvay Pharmaceuticals B.V. | 1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
WO2004058255A1 (en) * | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | 4, 5-diarylthiazole derivatives as cb-1 ligands |
Non-Patent Citations (7)
Title |
---|
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, GERDEMAN G L ET AL: "CB1 cannabinoid receptors are critical for induction of striatal long term depression" XP002271460 Database accession no. PREV200100520232 & SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, page 1024, 31st Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 10-15, 2001 ISSN: 0190-5295 * |
DYCK, BRIAN ET AL: "Potent imidazole and triazole CB1 receptor antagonists related to SR141716" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 14(5), 1151-1154 CODEN: BMCLE8; ISSN: 0960-894X, 2004, XP001197288 * |
HASSAN, HODA Y. ET AL: "Design and synthesis of some new 1H-1,2,4-triazoles of potential antiinflammatory and analgesic activities" BULLETIN OF PHARMACEUTICAL SCIENCES, ASSIUT UNIVERSITY , 17(1), 27-39 CODEN: BPAUEC, 1994, XP008033363 * |
JAGEROVIC N ET AL: "A NOVEL CLASS OF HETEROCYCLIC CANNABINOIDS: DESIGN, PREPARATION, IN VITRO AND IN VIVO STUDIES OF 1,2,4-TRIAZOLES" DRUGS OF THE FUTURE, BARCELONA, ES, vol. 27, no. SUPPL A, 1 September 2002 (2002-09-01), page 284, XP001121041 ISSN: 0377-8282 cited in the application * |
M. H. BEERS AND R. BERKOW: "The Merck Manual of Diagnosis and Therapy, Seventeenth Edition" 1999, MERCK RESEARCH LABORATORIES , WHITEHOUSE STATION, N.J. , XP002271459 page 2255, column 2 - page 2258 * |
OCHI TAKEHIRO ET AL: "The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 391, no. 1-2, 10 March 2000 (2000-03-10), pages 49-54, XP001197357 ISSN: 0014-2999 * |
TANAKA A ET AL: "Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2 substituted- thiazoles" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 8, 15 April 1994 (1994-04-15), pages 1189-1199, XP002268971 ISSN: 0022-2623 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7348456B2 (en) | 2002-12-19 | 2008-03-25 | Merck & Co., Inc. | Substituted amides |
US7576239B2 (en) | 2002-12-19 | 2009-08-18 | Merck & Co., Inc. | Substituted amides |
EP1680106B1 (en) * | 2003-10-24 | 2009-08-05 | Solvay Pharmaceuticals GmbH | Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors |
US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
US7777036B2 (en) | 2004-09-20 | 2010-08-17 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
US8026360B2 (en) | 2004-09-20 | 2011-09-27 | Xenon Pharmaceuticals Inc. | Substituted pyridazines as stearoyl-CoA desaturase inhibitors |
US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
US8039497B2 (en) | 2006-11-10 | 2011-10-18 | Laboratorios Del Dr. Esteve, S.A. | 1,2,4-triazole derivatives as sigma receptor inhibitors |
US8349878B2 (en) | 2006-11-10 | 2013-01-08 | Laboratorios Del Dr. Esteve, S.A. | 1,2,4-triazole derivatives as sigma receptor inhibitors |
Also Published As
Publication number | Publication date |
---|---|
RU2006117627A (en) | 2007-12-10 |
MXPA06004434A (en) | 2006-06-20 |
CA2543338A1 (en) | 2005-05-06 |
BRPI0415851A (en) | 2007-01-02 |
WO2005039550A3 (en) | 2007-03-22 |
AU2004283056A1 (en) | 2005-05-06 |
JP2007513872A (en) | 2007-05-31 |
EP1753413A2 (en) | 2007-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050124660A1 (en) | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds | |
EP2285366B1 (en) | Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules | |
US20230059381A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
WO2006045799A2 (en) | Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions | |
KR20100072024A (en) | Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer | |
KR20140130179A (en) | Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders | |
WO2005039550A2 (en) | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds | |
WO2016126707A1 (en) | Apilimod compositions and methods for using same | |
EP1956908A2 (en) | Certain compositions and methods of treatment | |
WO2006118307A1 (en) | Therapeutic agent for pain | |
WO2006118212A1 (en) | Agent for preventing and treating pancreatitis | |
JPH08506593A (en) | Cancer treatment | |
KR20030016222A (en) | Preventives/remedies for postoperative stress | |
US20090281143A1 (en) | Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity | |
EP1680106B1 (en) | Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors | |
US20050143441A1 (en) | Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
WO2009151862A1 (en) | Method of treatment | |
CA2543197A1 (en) | Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors | |
TW200530219A (en) | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds | |
JP2007512267A (en) | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | |
WO2006035760A1 (en) | Drug for treating skin disease | |
JPWO2010047369A1 (en) | Treatment for diabetic nephropathy | |
WO2005102332A1 (en) | Therapeutic agent for arthrosis deformans | |
CA2423423A1 (en) | Medecines of ulcerative colitis | |
EP3215154A1 (en) | Salts and compositions useful for treating disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480030116.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004817279 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2543338 Country of ref document: CA Ref document number: 2004283056 Country of ref document: AU Ref document number: PA/a/2006/004434 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006536096 Country of ref document: JP |
|
ENP | Entry into the national phase in: |
Ref document number: 2004283056 Country of ref document: AU Date of ref document: 20041022 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004283056 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006117627 Country of ref document: RU |
|
ENP | Entry into the national phase in: |
Ref document number: PI0415851 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004817279 Country of ref document: EP |